Conclusions and Significance: These findings support previous reports in the literature that correlate EBV seronegativity, younger age at transplant, and liver versus kidney transplantation with increased incidence of PTLD.
However, long-term patient (p = 0.798) and graft survival (p = 0.454) were not influenced by the PS in multivariate analysis (adjusted for living donor transplantation, number of operative revisions, recipient age at transplant and era; all p < 0.001).
Eighty three patients (76%) were in CP at transplant and ninety-three patients (84.5%) had never received TKI prior to transplantation.
But the frequency of these procedures has not risen dramatically, because of an acute shortage of donor hearts, strict eligibility standards for potential recipients and caution at transplant centers that do not want to jeopardize success averages with risky operations.
At transplant time, Fusarium spp. densities in soil were generally similar among most brassica treatments but fumigated plots generally had less Fusarium.
Fourteen patients with average risk AML received RIC alloHSCT and post-GO consolidation: median age 13.5 years at transplant (range, 1 to 21), male-to-female 8 6, and disease status at alloHSCT 11 CR1 and 3 CR2.
Two types (main factors of variability) of treatments were applied, i.e. by blending the above products with the substrate at transplant, and by fertigation using the soluble hydrolysates only.
The resulting damage to the hepatocytes presumably results in varying levels of organ dysfunction up to and including primary hepatic nonfunction at transplant.
The median age at transplant was 52 years.
Median age at transplant was 60 19-711).
Mean age at transplant was 5.7 months (range, 3 9 months).
